Gabapentin News and Research

RSS
Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain.
Epilepsy drugs analyzed for causing increased risk of suicide in patients

Epilepsy drugs analyzed for causing increased risk of suicide in patients

GSK, XenoPort disappointed with GSK1838262/XP13512 phase 2b study for migraine headaches

GSK, XenoPort disappointed with GSK1838262/XP13512 phase 2b study for migraine headaches

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

FDA's acceptance for filing of DM-1796 NDA triggers $10M milestone payment to Depomed

FDA's acceptance for filing of DM-1796 NDA triggers $10M milestone payment to Depomed

Gabapentin shows effective in patients with locked-in syndrome, opsoclonus-myoclonus syndrome

Gabapentin shows effective in patients with locked-in syndrome, opsoclonus-myoclonus syndrome

FDA accepts Depomed's DM-1796 NDA for pain after shingles

FDA accepts Depomed's DM-1796 NDA for pain after shingles

Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting

Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting

Mylan subsidiary receives FDA approval for generic version of Neurontin Tablets

Mylan subsidiary receives FDA approval for generic version of Neurontin Tablets

Depomed attributes 56% increase in first-quarter revenue to $5.8M increase in Glumetza product sales

Depomed attributes 56% increase in first-quarter revenue to $5.8M increase in Glumetza product sales

European patent for XenoPort's investigational compound is valid

European patent for XenoPort's investigational compound is valid

XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

Depomed licensee submits DM-1796 NDA for management of PHN

Depomed licensee submits DM-1796 NDA for management of PHN

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

FDA issues Complete Response Letter for Horizant in treatment of RLS

FDA issues Complete Response Letter for Horizant in treatment of RLS

PROMETA Treatment Program rapidly reduces cravings for methamphetamine subjects: Study

PROMETA Treatment Program rapidly reduces cravings for methamphetamine subjects: Study

Depomed expands patent portfolio around extended release gabapentin formulation technology

Depomed expands patent portfolio around extended release gabapentin formulation technology

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

Depomed plans additional Serada Phase 3 trial for treatment of menopausal hot flashes

Depomed plans additional Serada Phase 3 trial for treatment of menopausal hot flashes

Antiepileptic drugs may have a possible protective effect against seizure disorders

Antiepileptic drugs may have a possible protective effect against seizure disorders

Astellas Pharma and XenoPort submit NDA in Japan for PMDA approval

Astellas Pharma and XenoPort submit NDA in Japan for PMDA approval